|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1800 CONCORD PIKE, P.O. BOX 15437 |
Address2 |
|
City | WILMINGTON |
State | DE |
Zip Code | 19850-5437 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 54073-12
|
||||||||
|
6. House ID# 349750000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Jamie Bell |
Date | 1/20/2023 4:16:56 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 483/S. 350 - Newborn Screening Saves Lives Act;
H.R. 1730/S. 670- Speeding Therapy Access Today Act
H.R. 1946, S. 1873. Cancer Moonshot Items related to the Administrations Cancer Moonshot initiative;
H.R. 5030/ S. 2706 DIVERSE Trials Act
HR 5376, Inflation Reduction Act reconciliation bill; Medicare price negotiation provision and Part D redesign; Preventative healthcare services and screenings; Issues related to preventative services and screenings for underrepresented communities
H.R. 6000 Cures 2.0 Act;
H.R. 6584 Diverse and Equitable Participation in Clinical Trials Act;
H.R. 6963 - Accelerated Approval Integrity Act;
H.R. 6996 Accelerating Access for Patients Act;
H.R.7667 - Food and Drug Amendments of 2022;
S. 1548, H.R. 3085/H.R. 7845. ENACT Act of 2021
S.4348 - FDASLA Act of 2022; General issues related to rare disease and orphan drugs; Reauthorization of the FDA User Fee Act; FDA modernization policy issues; Reauthorization of newborn screening programs; general issues related to health equity in rare disease and clinical trials; general issues related to diagnostics for patients with rare diseases; general issues related to pharmacy benefit managers (PBMs); general issues related to insurance coverage of specialty treatments
Issues related to clinical trial diversity
COVID-19; COVID-19 vaccine and therapy development
Climate, sustainability, and environment; Sustainability & Zero Carbon; Items related to environmental sustainability (including eliminating GHG emissions from pMDIs) and our Ambition Zero Carbon efforts.
E-Labeling
EVUSHELD
Issues related to repeal of the Medicaid AMP Cap.
Issues related to drug pricing, IRA
Drug Regulation, Approval, Clinical Trial Diversity and FDA User Fees;
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Thad |
Flood |
|
|
|
Katie |
Jones |
|
|
|
Caroline |
Quat |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act;
H.R. 19 - Lower Costs, More Cures Act;
H.R. 1946, S. 1873. Medicare Multi-Cancer Early Detection Screening Coverage;
H.R. 2617-accelerated approval in the Omnibus year end
H.R. 4065, S. 1971 (section 101), P.L. 117-328, H.R. 2617 Kidney disease screening, Expanding Medicare annual wellness benefit to include kidney disease screening.
H.R. 5260 - Reduced Costs and Continued Cures Act;
HR. 5376- Inflation Reduction Act; Build Back Better Act;
CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure;
Preventative healthcare services and screenings Issues related to preventative services and screenings for underrepresented communities
IRA implementation, Pub. L. 117-169 Medicare Reform(s); Issues related to Medicare Part B and Part D pricing reform.
General issues related to patient access to rare disease therapies, Part B and Part D drugs; issues related to home infusion for Part B patients; Center for Medicare and Medicaid Innovation (CMMI) policy issues; value-based payment arrangements; efforts to improve coding, coverage, and access for rare disease therapies; issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies; general issues related to diagnostic reimbursement
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Thad |
Flood |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Caroline |
Quat |
|
|
|
Katie |
Jones |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 7559 E-labeling; and issues related to appropriations hold on funding for a 2014 FDA rule that would provide electronic flexibilities related to package inserts (PI).
340B; Issues related to the 340B drug discount program
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Caroline |
Quat |
|
|
|
Thad |
Flood |
|
|
|
Katie |
Jones |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
IP and Antitrust;
H.R. 2883- Stop Stalling Access to Affordable Medications
H.R. 2891- Preserve Access to Affordable Generics and Biosimilars Act
H.R. 2873- Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
H.R. 7032- Increasing Transparency in Generic Drug Applications Act of 2022
S. 1435- Affordable Prescriptions for Patients Act of 2021
S. 1425- Stop STALLING Act
Trade; Supply Chain and Manufacturing; H.R. 4521-United States Innovation and Competition Act of 2021, H. Rept. 117-235
Trade; Issues related to the World Trade Organization (WTO) waiver on Trade-related Aspects of Intellectual Property Rights (TRIPS) for COVID-19 vaccines
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Aaron |
Hunter |
|
|
|
Helen |
Dwight |
|
|
|
Elizabeth |
Brooks |
|
|
|
Katie |
Jones |
|
|
|
Thad |
Flood |
|
|
|
Caroline |
Quat |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 2623 - Camerons Law
H.R. 5376 - Build Back Better Act
Issues related to the Orphan Drug Tax Credit
Issues related to the deduction of research and development expenditures
Issues related to corporate and international tax reform
S. 749/H.R 1304 - American Innovation and Jobs Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Elizabeth |
Brooks |
|
|
|
Katie |
Jones |
|
|
|
Thad |
Flood |
|
|
|
Caroline |
Quat |
|
|
|
Aaron |
Hunter |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 2617,Consolidated Appropriations Act, 2023
H.R. 7559 E-labeling; and issues related to appropriations hold on funding for a 2014 FDA rule that would provide electronic flexibilities related to package inserts (PI).
H.R. 8239/S. 4661, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
H.R. 8295/S. 4659,Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act,
H. Rept. 117-392, H. Rept. 117-403, H. Res. 1531. CTD, accelerated approval in the Omnibus year end, Consolidated Appropriations Act, 2023; P.L. 117-328.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Thad |
Flood |
|
|
|
Katie |
Jones |
|
|
|
Caroline |
Quat |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 2873- Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
H.R. 2883- Stop Stalling Access to Affordable Medications
H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
H.R. 2891- Preserve Access to Affordable Generics and Biosimilars Act
H.R. 7032- Increasing Transparency in Generic Drug Applications Act of 2022
S. 1425- Stop STALLING Act
S. 1435- Affordable Prescriptions for Patients Act of 2021
TRIPS / IP Waiver
Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform, and Antitrust;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Thad |
Flood |
|
|
|
Katie |
Jones |
|
|
|
Caroline |
Quat |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
Climate, sustainability, and environment; Sustainability & Zero Carbon; Items related to environmental sustainability (including eliminating GHG emissions from pMDIs) and our Ambition Zero Carbon efforts.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thad |
Flood |
|
|
|
Katie |
Jones |
|
|
|
Caroline |
Quat |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Helen |
Dwight |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Drug Regulation, Approval, Clinical Trial Diversity and FDA User Fees; Cancer Moonshot Items related to the Administrations Cancer Moonshot initiative;
H.R. 6000-CURES Act 2.0
H.R. 5030/ S. 2706- DIVERSE Trials Act
H.R. 6584- DEPICT Act
H.R. 3085/S. 1548- ENACT Act of 2021
H.R. 7845- NIH Clinical Trial Diversity Act of 2022
H.R. 1946/, S. 1873- Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Aaron |
Hunter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
IP and Antitrust;
H.R. 2883- Stop Stalling Access to Affordable Medications
H.R. 2891- Preserve Access to Affordable Generics and Biosimilars Act
H.R. 2873- Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
H.R. 7032- Increasing Transparency in Generic Drug Applications Act of 2022
S. 1435- Affordable Prescriptions for Patients Act of 2021
S. 1425- Stop STALLING Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Aaron |
Hunter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |